Skip to content

Metabolic phenotyping of individuals with abdominal obesity and high levels of hepatic fat before and after dietary interventions

Metabolic phenotyping of individuals with abdominal obesity and high levels of hepatic fat before and after dietary interventions - Belly Fat Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40205
Enrollment
110
Registered
2014-06-03
Start date
2014-10-20
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

algehele gezondheid, metabole gezondheid abdominal fat Fatty liver

Interventions

Allocation to one of the two designed dietary advices, counselling by professional dieticians. Both diets are based on a caloric restriction of 30%. (1) Dietary advice based on a more Western diet

Sponsors

Wageningen Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Age 40-70y at the time of recruitment BMI >27kg/m2 or waist circumference >102cm (males) or >88cm (females)

Exclusion criteria

Exclusion criteria: Hb levels 30g (men) or >20g (women) Tobacco smoker Abuse of drugs Any medical conditions or (metal) devices interfering with or posing a risk for the participant in 1H-MRS/MRI scanning (e.g. claustrophobia, pace maker, surgical screws/pins, artificial joints or heart valves, etc.) Diagnosed with any long-term medical condition (i.e. cardiovascular disease, gastrointestinal disease, renal dysfunction) Use of medications known to interfere with glucose or lipid homeostasis (i.e. corticosteroids) Allergic to fish oil or unwilling to consume fish oil supplements Unwilling to comply with dietary guidelines Restricted to a vegetarian dietary regime

Design outcomes

Primary

MeasureTime frame
Lipid accumulation in the liver (MRS) Body fat distribution (MRI) Physical fitness (VO2 max in a maximal exercise test) After a challenge meal: Metabolic plasma markers (cardio-metabolic risk factors, gut function, adipose tissue and muscle health) Peripheral blood mononuclear cells (gene expression patterns) Satiety and well-being (questionnaires) Adipose tissue en muscle biopsies (genome/epigenome determinations) Vascular functions (vascular health, blood pressure, aterial stiffness)

Secondary

MeasureTime frame
Brain activity (fMRI) Olfactory test Questionnaire on food preferences

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)